ASIA THERAPEUTICS INVESTORS2019-05-28T08:35:59-04:00

ASIA THERAPEUTICS INVESTORS

This panel features therapeutics investments in the perspective of Asia-based firms, or those with strong expertise in Asian markets. Topics may include:

  • Current areas of interest
  • Market landscape in Asian countries – Similarities & differences
  • Common issues when working with firms with Asian angles 
  • Investment process
  • Successful deals

Panelists will discuss how they evaluate therapeutics opportunities in the perspective of the Asian industry. The discussion will touch upon markets in different countries within Asia, and how companies can effectively enter these markets. Panelist will also discuss how companies could approach Asia based investors, and how they can effectively differentiate themselves in a crowded space.

Moderator

Shaoyu Chang, Vice President, FC Capital

Shaoyu is Vice President for FC Capital, a China-based VC/PE fund specialized in cross-border investments. With parallel RMB and USD funds under management, FC cultivates and invests in early- and growth-stage ventures, with a focus on sector leaders in biopharma, medical technology, and data analytics. Previously, Shaoyu served as Investment Manager for Virtus Inspire (VI) Ventures. Prior to that, Shaoyu was Director of Investor Research at LSN and Research Scholar at Duke University. Shaoyu received Master of Public Health from Harvard Chen School of Public Health and M.D. from National Taiwan University. Shaoyu is US Regulatory Affairs Certified with robust knowledge in pharmaceutical development.

Panelists

Andy Li, Founding Partner, BioSense Global

Andy has more than 25 years of biomedical research and biopharmaceutical industry experience with proven track records in global drug development in multiple therapeutic areas, alliance management, and business development. He previously held management positions at GSK, Abbott and Daiichi Sankyo. During his extensive career, Andy worked directly on highly successful projects and products, including HUMIRA and Olmesartan. He also managed and led the development, registration, and commercialization efforts in key markets, including the U.S., Europe, Japan, China, Korea, Taiwan, Brazil and others. Currently he is the co-founder, CEO and President of BioSense Global LLC. PhD from Albert Einstein College of Medicine and MBA from Duke University.• PhD from Albert Einstein College of Medicine and MBA from Duke University.

Mark Tang, Managing Director, Good Health Capital

Mark Tang is a managing director of Good Health Capital, a healthcare private equity firm with offices in Asia and New York. Mark has over two decades of experience in the field of biotechnology as an entrepreneur, educator, advisor and investor. He was formerly a research associate at Rockefeller University and a biotech director at Rutgers Business School. Mark holds several degrees including an MPH from Harvard.

Weiyong Sun, Senior Director, Specialty Medicine Search & Evaluation, Daiichi Sankyo

Dr. Weiyong Sun is currently Senior Director, Searching and Evaluation, Global Business Development and Licensing at Daiichi Sankyo Group. He joined Daiichi Sankyo Japan in April 2002. He was involved in a broad range of R&D activities from target discovery to clinical development of a number of anti-diabetes drugs. In October 2007, Dr. Sun was elected to be assigned to work for Daiichi Sankyo Research Institute in the U.S. He was responsible for identifying and evaluating in-licensing, partnering and research collaboration opportunities. His current focus is in Pain, Cardio-Renal, Ophthalmology and Rare Disease. Dr. Sun received an M.D. from Beijing Medical University (now Peking University Medical School), a Ph.D. in Biochemistry from the University of Tokyo and an MBA from Columbia Business School. He was a postdoctoral fellow in the Blood Research Institute, Medical College of Wisconsin.

Zishan Haroon, Chairman and General Partner, Julz Co LLC

Dr. Haroon brings over two decades of experience in venture, private equity, corporate/business development and academia (with direct transactional and operational exposure of 15+ years in China) to lead Julz, a US based fund focused in healthcare opportunities worldwide. Julz has offices in NC and Suzhou China to exploit the tremendous opportunity offered in healthcare in both US and China. The investment spans all facets from innovative drugs, devices to services such as hospitals and diagnostic labs.

Go Back to Agenda